Ejaculatory dysfunction in men with diabetes mellitus.

Diabetes mellitus (DM) is a metabolic disorder that is characterized by elevated blood glucose levels due to absolute or relative insulin deficiency, in the background of β-cell dysfunction, insulin resistance, or both. Such chronic hyperglycemia is linked to long-term damage to blood vessels, nerves, and various organs. Currently, the worldwide burden of DM and its complications is in increase.

Gene Variants in Premature Ejaculation: Systematic Review and Future Directions.

Introduction: A growing number of genetic association studies have been performed to investigate the association between the genetic susceptibility alleles and the risk of premature ejaculation (PE); however, the results remain inconclusive.

Objectives: This systematic review aimed: (i) to determine whether an association exists between gene(s) or allelic variant(s) and PE; (ii) to assess whether the associations are consistent across studies in magnitude and direction, and (iii) to identify any limitation, gap, or shortcoming in the included studies.

Methods: The literature search was conducted in PubMed, MEDLINE, Scopus, Cochrane Library, EMBASE, Academic Search Complete, Google Scholar, and CINAHL databases.

Correlation of Adiponectin With Testosterone in Patients With and Without Type 2 Diabetes and Erectile Dysfunction.

The aim of this study was to evaluate the levels of adiponectin in diabetic patients with and without erectile dysfunction (ED). In addition, the correlations of adiponectin with the scores of international index of erectile function (IIEF) and total testosterone levels were explored in diabetic and nondiabetic patients with ED. The study included three groups: Type 2 Diabetic patients (T2DM) with and without ED and a third nondiabetics with ED group, each of 29 patients.

Delayed Ejaculation: Pathophysiology, Diagnosis, and Treatment.

Delayed ejaculation (DE) is a poorly defined and uncommon form of male sexual dysfunction, characterized by a marked delay in ejaculation or an inability to achieve ejaculation. It is often quite concerning to patients and their partners, and sometimes frustrates couples' attempts to conceive. This article aims to review the pathophysiology of DE and anejaculation (AE), to explore our current understanding of the diagnosis, and to present the treatment options for this condition.

Tramadol Abuse and Sexual Function.

Introduction: Tramadol exhibits an effect profile similar to that of opioid agonists, and tramadol abuse seems to be a problem for a number of countries. The relationship between tramadol and sexual function appears to be controversial. Men with premature ejaculation (PE) may benefit from taking tramadol off label; however, these patients live "on a knife's edge" and are exquisitely sensitive to develop other sexual dysfunctions.

The drug treatment of delayed ejaculation.

Delayed ejaculation (DE) is an uncommon and a challenging disorder to treat. It is often quite concerning to patients and it can affect psychosocial well-being. Here we reviewed how DE is treated pharmacologically .

Therapeutic targets for premature ejaculation.

Premature ejaculation (PE) is the most common male sexual complaint, and may exert a profound negative impact on the man's life and partnership. Using currently available treatment alternatives (e.g.

Further evidence of the clinical, hormonal, and genetic heterogeneity of Klinefelter syndrome: a study of 216 infertile Egyptian patients.

This study aims to provide further insight into the phenotypic heterogeneity of Klinefelter syndrome (KS) by presenting clinical, hormonal, and genetic data from a large series of Egyptian infertile patients with KS. A retrospective case series of KS patients was studied over a period from January 2003 to April 2010. All patients underwent a complete history and physical examination; color duplex examination; semen analysis; measurement of total testosterone (T), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), and prolactin (PRL); and chromosomal typing.

Peyronie's disease: perspectives on therapeutic targets.

Introduction: Peyronie's disease (PD) is an acquired benign connective tissue disorder of the penis, characterized by the development of fibrotic plaques, that can cause different degrees of bending, narrowing or shortening. Medical treatment for PD remains a major challenge. Impressive progress in our understanding of the molecular mechanisms of PD pathogenesis has uncovered several promising molecular targets for antifibrotic treatments.

Exploration of therapeutic targets for sexual dysfunctions: lessons learned from the failed stories.

Introduction: The ratio between research and successful targets in a disease class gives a good indication about the extent of the exploration of additional targets for diseases in that class. This ratio is still very low for the field of sexual medicine. 'Failures' in drug development can be highly instructive, but are not often addressed.

Primary lifelong delayed ejaculation: characteristics and response to bupropion.

Introduction: In contrast to premature ejaculation and secondary delayed ejaculation (DE), primary lifelong DE has not been studied extensively. In addition, there is no approved drug treatment.

Aims: To explore the clinical and laboratory characteristics of a series of men complaining of lifelong DE and to report the response to bupropion.

Pharmacogenetics and pharmacogenomics of sexual dysfunction: current status, gaps and potential applications.

Although treatment of different types of sexual dysfunction has improved in the past decade with the introduction of phosphodiesterase type 5 inhibitors and selective serotonin reuptake inhibitors, response rates to these targeted therapies are variable. There are a number of studies in the published literature that provide proof-of-concept that genetic variation contributes to the variable response. Pharmacogenomics will most likely be one part of our therapeutic armamentarium in the future and will provide a stronger scientific basis for optimizing drug therapy on the basis of each patient's genetic constitution.

Premature ejaculation: focus on therapeutic targets.

Background: Premature ejaculation (PE) is poorly defined but the most common male sexual complaint. It can be treated with strategies including oral pharmacotherapy, topical anaesthetics, behavioural therapy and surgery. Although PE is treatable in most, but not all, patients by currently available modalities, long term success rates have been disappointing.

Pharmacologic treatment of rapid ejaculation: levels of evidence-based review.

Rapid (premature) ejaculation (RE) is defined as persistent or recurrent ejaculation with minimal sexual stimulation before, upon, or shortly after penetration and before it is wished by the man or his partner. RE is the most frequently encountered sexual complaint of men and couples. Estimates suggest that as many as one third of all sexually active men suffer from RE.

Can smooth muscle represent a useful target for the treatment of rapid ejaculation?

Rapid ejaculation is probably the most common form of male sexual dysfunction. Current research into the treatment of the condition has focused on centrally acting or topical desensitizing agents; however, no treatment has yet been approved. An alternative approach could be to develop drugs that act directly upon the target organ itself and our increasing knowledge of the molecular biology of the accessory sex organs makes this a realistic possibility.

Phosphodiesterase 5 inhibitors in rapid ejaculation: potential use and possible mechanisms of action.

Rapid (premature) ejaculation (RE) is a very common sexual disorder. This condition may be primary or secondary to underlying disease. Control of RE has been primarily focused on behavioural therapy, topical anaesthetics, tricyclic antidepressants and selective serotonin reuptake inhibitors; however, an approved treatment does not exist.

Pityriasis amiantacea: a clinical and etiopathologic study of 85 patients.

Background: Studies on pityriasis amiantacea (PA) in the literature are limited and mostly retrospective. We prospectively analyzed the clinical and etiopathologic factors in a large series of PA diagnosed at our department within a defined period (2000-01).

Methods: All PA patients who attended our department were evaluated clinically and underwent bacteriologic, mycologic, and histopathologic examinations.

Leprosy in a high-prevalence Egyptian village: epidemiology and risk factors.

Background: The epidemiology of leprosy in rural Egypt is unknown. This prospective household survey was conducted in a high-prevalence Egyptian village in order to explore the epidemiologic characteristics of the disease and to determine the possible socioeconomic and HLA genotype risk factors.

Methods: The subjects of the study were the residents of Kafr-Tambul village in the Dakahlia governorate, Egypt.